Biolevate Has Secured €30 Million for AI Platform
The Paris-based startup aims to scale its agentic AI platform for life sciences workflows following a Series A round.
Updated on Sept. 22, 2026 in Artificial Intelligence
Live Poll
Do you trust AI automation to handle regulatory and safety-critical tasks in the healthcare industry?
Biolevate, a developer of agentic AI platforms for life sciences, has announced a €30 million Series A funding round. The platform is designed to assist with complex tasks like systematic literature reviews and regulatory intelligence.
Why it matters
The investment accelerates the company's efforts to automate high-stakes research workflows and scale operations internationally. By grounding AI output in source evidence, the firm attempts to solve reliability issues in scientific data processing.
Biolevate's platform supports up to 100,000 concurrent agents, achieving a 16x acceleration in systematic literature reviews and an 80 per cent efficiency gain in regulatory intelligence compared to manual processes.
The players
Biolevate
A Paris-based company providing an agentic AI platform that automates systematic literature reviews and regulatory intelligence for life sciences enterprises.
RAISE France
A venture capital firm focused on supporting growth-stage technology companies that co-led this funding round.
Orange Ventures
The venture arm of the international telecommunications group that co-led the Series A financing.
The details
The platform functions by converting scientific and regulatory knowledge into auditable workflows that maintain strict grounding in source evidence. It operates as an agentic system—a framework where autonomous AI units perform multi-step tasks—to execute complex research chores. The startup has already filed two patent applications in Europe to protect its architecture and currently serves more than a dozen enterprise clients.
Timeline
2024: Biolevate raised its seed round.
September 22, 2026: Biolevate announced Series A funding.
Next 12 months: Biolevate expects to double its workforce.
The Tech Race
Biolevate's expansion into the U.S. market follows an industry-wide pivot toward agentic AI platforms for life sciences workflows. This funding positions the company to compete against existing automated research tools by scaling its concurrent agent capacity.
Enterprise customers in life sciences will likely see expanded support and faster deployment times as the company opens its new Boston office. Future integration will depend on the platform's ability to maintain high compliance standards as it scales its current enterprise service model.
The takeaway
The company's rapid growth indicates strong enterprise demand for specialized, audit-ready AI agents in scientific research. Observers should track whether the firm hits its target of doubling its total workforce within the next year to support its international expansion.
Further reading
For more on the current state of autonomous systems, visit Artificial Intelligence.
Live Poll
Do you trust AI automation to handle regulatory and safety-critical tasks in the healthcare industry?
